EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

TREATMENT OF NEWLY DIAGNOSED POEMS SYNDROME: BORTEZOMIB OR LENALIDOMIDE? EXPERIENCE FROM TWO COUNTRIES

Deniz Ozmen, Francesco Autore, Tuba Ozkan, Gunel Musayeva, Zeliha Birsin, Daniele Mannina, Federica Lessi, Daniele Derudas, Umut Yilmaz, Tugrul Elverdi, Ahmet Emre Eskazan, Muhlis Cem Ar und 4 weitere

Mediterranean Journal of Hematology and Infectious Diseases · 31.10.2026 · 18 (1) · e2026084

DOI: 10.4084/mjhid.2026.084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 31.10.2026. Verfasst von Deniz Ozmen und 15 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes) syndrome is a rare plasma cell disorder in which treatment selection remains largely empirical. Lenalidomide-based regimens are generally preferred in the first line due to concerns about bortezomib-induced neurotoxicity, despite limited comparative evidence. We aimed to directly compare the real-world efficacy and safety of first-line bortezomib- versus lenalidomide-based regimens.

Methods

In this retrospective multicenter cohort, 26 newly diagnosed POEMS patients between 2005 and 2024 from Türkiye and Italy were included. Nine patients received bortezomib-based therapy and 17 received lenalidomide–dexamethasone. Primary endpoint was overall survival (OS); secondary endpoint was hematologic response.

Results

Bortezomib-based therapy achieved significantly higher rates of deep response (≥VGPR, defined as complete response or very good partial response) compared with lenalidomide (88.9% vs 35.3%; p = 0.013). Despite higher prevalence of baseline neuropathy in the bortezomib group (77.8% vs 29.4%; p = 0.038), no treatment-emergent worsening of neuropathy was observed. Model-based 5-year overall survival was 86.6% with bortezomib and 80.7% with lenalidomide (time ratio [TR] 0.61, 95% CrI 0.04–6.78), demonstrating no evidence of a survival difference between the two strategies, with similar autologous transplantation rates and toxicity profiles.

Conclusion

In this multicenter real-world cohort, bortezomib-based first-line therapy was associated with markedly deeper hematologic responses without excess neurotoxicity or survival disadvantage. These findings suggest that bortezomib-based therapy may represent an effective upfront option in selected patients and support re-evaluation of first-line strategies in prospective studies.

Zitieren

APA

Ozmen, D., Autore, F., Ozkan, T., Musayeva, G., Birsin, Z., Mannina, D., Lessi, F., Derudas, D., Yilmaz, U., Elverdi, T., Eskazan, A. E., Ar, M. C., Baslar, Z., Bramanti, S., Laurenti, L., & Salihoglu, A. (2026). TREATMENT OF NEWLY DIAGNOSED POEMS SYNDROME: BORTEZOMIB OR LENALIDOMIDE? EXPERIENCE FROM TWO COUNTRIES. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026084. https://doi.org/10.4084/mjhid.2026.084

Vancouver

Ozmen D, Autore F, Ozkan T, Musayeva G, Birsin Z, Mannina D, et al. TREATMENT OF NEWLY DIAGNOSED POEMS SYNDROME: BORTEZOMIB OR LENALIDOMIDE? EXPERIENCE FROM TWO COUNTRIES. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026084. doi:10.4084/mjhid.2026.084

BibTeX
@article{Ozmen2026,
  author = {Ozmen, Deniz and Autore, Francesco and Ozkan, Tuba and Musayeva, Gunel and Birsin, Zeliha and Mannina, Daniele and Lessi, Federica and Derudas, Daniele and Yilmaz, Umut and Elverdi, Tugrul and Eskazan, Ahmet Emre and Ar, Muhlis Cem and Baslar, Zafer and Bramanti, Stefania and Laurenti, Luca and Salihoglu, Ayse},
  title = {TREATMENT OF NEWLY DIAGNOSED POEMS SYNDROME: BORTEZOMIB OR LENALIDOMIDE? EXPERIENCE FROM TWO COUNTRIES},
  journal = {Mediterranean Journal of Hematology and Infectious Diseases},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {e2026084},
  doi = {10.4084/mjhid.2026.084}
}
Kostenlos starten →